Abstract:Colorectal cancer (CRC) is a serious threat to human health and survival. In recent years, the incidence of CRC is on the rise. Further, CRC research is a hotspot that attempts to provide solutions to difficulties experienced in the medical field. In the United States alone, approximately 150,000 patients were diagnosed with CRC in 2019, of which, approximately 50,000 died due to tumor progression. [ 1 ] Globally, CRC is the third most common malignant tumor and the second leading cause of cancer death. [ 2 ] In 2021, in the United States, the incidence of CRC accounted for 8% of the cancer cases, with a similar incidence and mortality observed in men and women. [ 3 ] The pathology and development of CRC is a continuous and progressive process (Fig. 1A). A colorectal adenoma (CRA) is recognized as a precancerous lesion of colon cancer. Relevant data indicate that more than 90% of CRC can develop from a colonic polyp, among which, CRA has a higher risk of malignancy. [ 4 , 5 ] It takes 5 to 10 years for a CRA to develop into CRC. Therefore, the prevention and treatment of clinically active CRA are of great significance to prevent the occurrence and development of CRC.

Exploring the mechanism of Tengli Kangliu Decoction in the prevention and treatment of colorectal cancer precancerous based on network pharmacology